Intravenous Infusions Plc (GHSE:IIL)

Market Cap	13.72M -32.7%
Revenue (ttm)	9.30M -62.7%
Net Income	-5.18M
EPS	-0.02
Shares Out	274.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.00 (5.60%)
Ex-Dividend Date	n/a

Volume	197,317
Average Volume	40,541
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	0.0400 - 0.0500
Beta	0.16
RSI	54.61
Earnings Date	Jan 26, 2026

About Intravenous Infusions

Intravenous Infusions Plc, a pharmaceutical company, engages in the manufacturing and marketing of intravenous infusions and small volume injectables for therapeutic purposes in Ghana and the West African sub-region. It offers pethidine, including Chloroquine Phosphate and quinine dihydrochloride injections. The company was incorporated in 1969 and is based in Koforidua, Ghana.

• Industry: Pharmaceutical Preparations
• Founded: 1969
• Country: Ghana
• Stock Exchange: Ghana Stock Exchange
• Ticker Symbol: IIL

Financial Performance

In 2025, Intravenous Infusions's revenue was 9.30 million, a decrease of -62.69% compared to the previous year's 24.94 million. Losses were -5.18 million, 706.0% more than in 2024.